

Supplemental Table 1: Release of lipid mediators from peritoneal neutrophils

Wt neutrophils from peritoneal lavages one day post thioglycolate injection were cultured in the absence or presence of Atglistatin. Media were collected from non-activated and activated cells (0.5 μ M A23187, 1 h). Data are shown as median (pg/ml) and range (n=6).

Pathway	Lipid mediator	Thioglycolate-stimulated				Thioglycolate +A23187-stimulated			
		-Atglistatin		+Atglistatin		-Atglistatin		+Atglistatin	
		median	range	median	range	median	range	media	range
COX-AA	6-keto-PGF1a	95	(29 - 467)	35*	(12 - 211)	152	(22 - 634)	94	(26 - 262)
COX-EPA	TxB3	3681	(2820 - 3961)	3159	(3002 - 3521)	2079	(1713 - 2525)	3142	(1940 - 3332)
COX-AA	TxB2	416	(170 - 527)	111*	(79 - 145)	241	(79 - 357)	77*	(61 - 99)
COX-AA	PGF2a	116	(58 - 145)	70	(54 - 74)	82	(65 - 105)	57	(53 - 61)
ROS, COX-AA	15-keto-PGF2a/ 8-iso-PGE2/ PGE2	1184	(617 - 1524)	343*	(252 - 434)	585	(319 - 1127)	230*	(147 - 320)
ROS, COX-AA	8-iso-PGE2/ PGE2	795	(364 - 1021)	190*	(132 - 227)	423	(194 - 704)	108*	(32 - 169)
COX-AA	PGD2	140	(105 - 177)	72	(65 - 73)	123	(77 - 201)	n.d.	
COX-DHGLA	PGD1	56	(51 - 57)	45	(44 - 45)	45	(44 - 51)	n.d.	
COX, ROS-AA	15-keto-PGE2/ 8-iso-15-keto PGE2	54	(49 - 59)	49*	(46 - 52)	55	(50 - 61)	47*	(46 - 52)
LOX-AA	LTE4	30	(27 - 35)	n.d.		99	(42 - 110)	33	(22 - 65)
COX-AA	PGJ2	20	(16 - 27)	15	(14 - 17)	18	(14 - 24)	n.d.	
LOX-AA	5(S).15(S)-DiHETE	n.d.		n.d.		78	(56 - 81)	62*	(57 - 68)
LOX-AA	LTB4	138	(137 - 153)	131*	(130 - 141)	971	(538 - 1252)	577*	(351 - 858)
LOX-AA	12-oxo-LTB4	n.d.		n.d.		195	(174 - 210)	172	(165 - 173)
LOX-AA	Tetranor-12(S)-HETE	58	(57 - 58)	60	(58 - 60)	58	(57 - 58)	58	(58 - 58)
COX-AA	12(S)-HHT	541	(269 - 739)	136*	(117 - 178)	311	(117 - 442)	104*	(77 - 135)
LOX-AA	5(S).6(S)-DiHETE	n.d.		n.d.		238	(185 - 284)	214	(160 - 274)
CYP-AA	5,6-DHET	168	(167 - 168)	167	(166 - 168)	167	(166 - 167)	167	(166 - 168)
CYP, LOX-AA	(\pm)18-HETE	41	(32 - 61)	41	(22 - 50)	22	(9 - 22)	24	(10 - 43)
LOX-EPA	12(S)-HEPE	n.d.		n.d.		142	(138 - 145)	140	(139 - 148)
CYP-AA	17(S)-HETE	154	(152 - 156)	152	(152 - 153)	151	(151 - 151)	152	(151 - 152)
LOX-EPA	5(S)-HEPE	189	(188 - 194)	186*	(185 - 187)	194	(191 - 203)	192	(187 - 192)
CYP, LOX-LA	(\pm)13-HODE	176	(47 - 885)	153	(90 - 216)	284	(120 - 615)	214	(59 - 345)
LOX-LA	(\pm)9-HODE	234	(104 - 805)	72	(27 - 107)	231	(72 - 428)	156	(59 - 204)
LOX, CYP-AA	15(S)-HETE	75	(57 - 91)	34*	(30 - 46)	88	(35 - 165)	48*	(17 - 85)
CYP, COX-AA	11-HETE	166	(89 - 232)	39*	(31 - 58)	101	(39 - 203)	28*	(10 - 61)
CYP, LOX-AA	8(S)-HETE	280	(244 - 303)	254	(230 - 267)	327	(267 - 407)	298	(222 - 393)
CYP, LOX-AA	12-HETE	15	(10 - 20)	19	(13 - 28)	72	(15 - 103)	51	(8 - 107)
LOX-AA	12-oxo-ETE	212	(210 - 213)	212	(210 - 212)	215	(211 - 220)	212	(212 - 216)
CYP, LOX-AA	5-HETE	40	(36 - 93)	18*	(13 - 33)	942	(519 - 1292)	613*	(257 - 929)
CYP-AA	(\pm)14,15-EET	135	(133 - 136)	n.d.		135	(134 - 136)	n.d.	
LOX-AA	5-oxo-ETE	295	(293 - 304)	n.d.		308	(300 - 316)	305	(291 - 315)
CYP-AA	(\pm)8,9-EET	509	(504 - 517)	500	(499 - 505)	502	(497 - 503)	498	(496 - 499)

n.d., not detected; presence vs. absence of Atglistatin, *p < 0.05